Boston Scientific stock slips as short interest jumps and Asian factory opens
Published on 09/17/2026 at 11:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Boston Scientific stock (ISIN US10117L1017) last closed at USD 43.87 on September 15, 2026 on the New York Stock Exchange, around 54.0 percent below its level at the start of 2026 and near the lower end of its recent trading range. As of mid-September 2026, the medical device maker is navigating a sharp rise in short interest alongside operational milestones, including the start of production at its first Asian factory in Penang, Malaysia.
Short interest surges while insiders buy
According to MarketBeat on September 16, 2026, short interest in Boston Scientific rose 74.4 percent between August 15 and August 31, 2026, reaching about 48.17 million shares, equivalent to roughly 3.3 percent of shares outstanding and a short-interest ratio of 2.3 days. Over the same period, insiders bought an estimated USD 9.4 million worth of stock in the prior 90 days, including notable purchases by CEO Michael Mahoney and director David Habiger, suggesting management confidence despite the heightened bearish positioning.
The short-interest build-up comes after a steep share-price decline. Per MarketBeat on September 16, 2026, Boston Scientific stock started the year around USD 95.29 and, at USD 43.87, was down about 54.0 percent year to date, implying a loss of more than half its market value since early 2026. For investors, this combination of elevated short interest and insider buying creates a tension between perceived downside risks and management’s view of long-term value.
Q2 FY26 results beat expectations
Fundamentally, the company’s latest reported quarter delivered solid growth. According to Yahoo Finance, Boston Scientific reported revenue of USD 5.44 billion in Q2 fiscal 2026, up from USD 5.07 billion in the year-ago quarter, corresponding to year-over-year growth of about 7.3 percent. Net earnings for Q2 fiscal 2026 reached roughly USD 907 million, implying a profit margin of around 16.7 percent for the period.
The company also exceeded earnings expectations. As summarized by MarketBeat, Boston Scientific delivered earnings per share of USD 0.86 in Q2 fiscal 2026, topping the Q2 FY26 consensus estimate of USD 0.83 referenced by Yahoo Finance. This EPS beat of about USD 0.03 per share underscores that the operating performance in the latest quarter was ahead of market expectations even as the stock price came under pressure.
Cyberattack fallout and political buying add context
The steep share-price decline in 2026 has been closely linked to an operational disruption. As Yahoo Finance reported on September 16, 2026, Boston Scientific suffered a cyberattack that disrupted manufacturing, order processing and shipments, prompting the company to withdraw its previous third-quarter and full-year outlook. The same report noted that by September 8, 2026, the company stated that its major distribution centers were shipping at or above normal levels, sterilization facilities were operating, and manufacturing had restarted at most plants, suggesting that much of the lost revenue could be delayed rather than permanently lost.
The article also highlighted that Boston Scientific stock was down about 50 percent year to date at that time, while some investors viewed the sell-off as overly severe given the recovery in operations. Notably, the piece pointed out that members of the US Congress, including Gilbert Ray Cisneros Jr. and Ro Khanna, disclosed purchases of Boston Scientific shares in August 2026, signaling that some political insiders see value at current levels even with the cyber-related risks.
Asian factory milestone and analyst view
Beyond the short-term disruption, Boston Scientific is expanding its global manufacturing footprint. According to The Edge Malaysia on September 17, 2026, the company’s first Asian factory in Penang, located in Batu Kawan Industrial Park, has commenced operations. This facility is intended to support the production of medical devices for global markets and signals Boston Scientific’s commitment to diversifying and strengthening its supply chain in Asia.
Despite the sharp share-price decline, the analyst community remains broadly constructive. MarketBeat notes that, as of mid-September 2026, Boston Scientific carries a consensus rating of Moderate Buy from 31 analysts, with 24 rating the stock Buy, five rating it Hold and two rating it Sell. The same overview cites an average analyst price target of about USD 71.46, implying upside of more than USD 27.00 per share compared with the recent closing price of USD 43.87, although individual targets and time horizons vary.
Stock level and valuation signal
On the valuation side, discounted cash flow analysis offers another perspective. A review by GuruFocus on September 16, 2026, estimated an earnings-based intrinsic value of USD 53.14 per share for Boston Scientific, around 21 percent above the contemporaneous market price of USD 43.87. By contrast, the same analysis put a free-cash-flow-based intrinsic value at USD 37.59, slightly below the current share price, underscoring how different valuation methods can yield divergent views of whether the stock is undervalued or fairly priced.
Price movements in September 2026 have also been volatile. Data cited by MarketBeat indicate that shares recently traded around USD 43.97 with a daily volume near 28.5 million shares, compared with an average volume of about 18.6 million. A separate performance overview on MarketBeat notes that Boston Scientific stock has fallen 56.1 percent over the past twelve months, highlighting the extent of the drawdown relative to both its own history and many healthcare peers.
Boston Scientific stock and recent reference price
For orientation, one recent reference price point is a close of USD 43.87 on the New York Stock Exchange on September 15, 2026, with the stock changing hands the following day around USD 43.91 in later trading, according to regional market data summaries. At this level, Boston Scientific stock trades significantly below the average analyst price target of USD 71.46 and modestly below the earnings-based intrinsic value estimate of USD 53.14, while still reflecting the heightened risk perception following the cyberattack and the surge in short interest.
Boston Scientific stock at a glance
- Company: Boston Scientific Corporation
- ISIN: US10117L1017
- Ticker: BSX
- Trading venue: New York Stock Exchange
- Price (as of September 15, 2026): 43.87 USD
- Market capitalization: 63.00 billion USD (as of September 15, 2026)
- Sector / Industry: Health Care / Medical Devices
- Index membership: S&P 500
